Table 2.
The role of pyroptosis in cancers.
| Cancer types | The function of pyroptosis | References |
|---|---|---|
| Lung cancer | 1. GSDMD promoted lung cancer development | [48, 49] |
| 2. P53 interacts with NLPR3 to promote pyroptosis and repress lung cancer development | ||
| Liver cancer | 1. DFNA5 inhibit HepG2 cell proliferation | [54, 55] |
| 2. The NLRP3 inflammasome is downregulated and represses HCC progression | ||
| Breast cancer | 1. GSDME and GSDMD repress breast cancer | [25, 60] |
| Gastric cancer | 1. GSDMD and GSDME repress the gastric cancer cells proliferation | [67, 68] |
| Colorectal cancer | 1. GSDMC promoted colorectal cancer development | [72–74] |
| 2. GSDMD inhibit colorectal cancer progression | ||
| 3. GSDME-mediated pyroptosis of epithelial cells promote the progression of colorectal cancer | ||
| Oesophageal squamous cell carcinoma | 1. GSDME represses oesophageal squamous cell carcinoma progression | [85] |
| Melanoma cancer | 1. GSDMC are upregulated and promote melanoma cancer progression | [87–89] |
| 2. BRAF and MEK inhibitors inhibit melanoma cancer progression via inducing pyroptosis | ||
| 3. pyroptosis can release HMGB1 and enhance the progression of melanoma | ||
| Acute myeloid leukaemia | 1. GSDMD are upregulated and represses leukaemia progression | [90] |
| Ovarian cancer | 1. GSDME is downregulated whereas GSDMD and GSDMC are upregulated and repress ovarian cancer progression | [91–93] |
| 2. lncRNA GAS5 and lncRNA HOTTIP represses ovarian cancer progression via inducing pyroptosis | ||
| Oral squamous cancer | 1. GSDME represses oral squamous cancer progression | [94] |
| Glioma | 1. GSDMD represses glioma progression | [96, 97] |
| 2. Caspase-1-mediated glioma cell pyroptosis inhibit glioma progression |